Stock 2877 CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials China Shineway Pharmaceutical Group Limited

Equities

2877

KYG2110P1000

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 09:08:20 14/05/2024 BST 		5-day change 1st Jan Change
9.89 HKD +1.44% Intraday chart for China Shineway Pharmaceutical Group Limited +7.15% +36.04%
03-29 China Shineway Pharmaceutical Group Grows 2023 Profit, Declares Interim 2024 Dividend MT
03-28 China Shineway Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 5,101 3,372 4,241 5,064 4,992 6,916 - -
Enterprise Value (EV) 1 1,559 -178.4 50.04 17.21 4,992 1,181 699.4 -183.6
P/E ratio 10.3 x 11.5 x 7.59 x 6.98 x 5.16 x 6.3 x 5.44 x 4.73 x
Yield 3.49% 7.16% 6.95% 4.77% - 6.19% 7.24% 8.22%
Capitalization / Revenue 1.89 x 1.27 x 1.32 x 1.28 x 1.11 x 1.32 x 1.14 x 0.99 x
EV / Revenue 0.58 x -0.07 x 0.02 x 0 x 1.11 x 0.23 x 0.12 x -0.03 x
EV / EBITDA 2.03 x -0.25 x 0.06 x 0.02 x 3.79 x 0.83 x 0.43 x -0.1 x
EV / FCF - - - - - 2.22 x 0.78 x -0.13 x
FCF Yield - - - - - 45% 129% -745%
Price to Book 0.89 x 0.58 x 0.72 x 0.79 x - 0.99 x 0.9 x 0.82 x
Nbr of stocks (in thousands) 773,403 754,600 755,400 755,400 755,400 755,400 - -
Reference price 2 6.595 4.469 5.614 6.703 6.608 9.156 9.156 9.156
Announcement Date 31/03/20 30/03/21 29/03/22 30/03/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,706 2,656 3,224 3,951 4,517 5,239 6,055 7,002
EBITDA 1 767.5 723.8 826 1,022 1,316 1,420 1,630 1,864
EBIT 1 562.5 515.4 643.6 835.8 1,139 1,280 1,506 1,754
Operating Margin 20.79% 19.41% 19.97% 21.16% 25.21% 24.43% 24.87% 25.05%
Earnings before Tax (EBT) 1 642.8 395 720.1 917 1,240 1,441 1,669 1,920
Net income 1 503.2 295 556.7 722.8 969.5 1,129 1,308 1,505
Net margin 18.59% 11.11% 17.27% 18.3% 21.47% 21.55% 21.61% 21.49%
EPS 2 0.6400 0.3900 0.7400 0.9600 1.280 1.453 1.682 1.936
Free Cash Flow 1 - - - - - 532 900 1,367
FCF margin - - - - - 10.15% 14.86% 19.52%
FCF Conversion (EBITDA) - - - - - 37.47% 55.2% 73.32%
FCF Conversion (Net income) - - - - - 47.11% 68.79% 90.86%
Dividend per Share 2 0.2300 0.3200 0.3900 0.3200 - 0.5670 0.6630 0.7530
Announcement Date 31/03/20 30/03/21 29/03/22 30/03/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 S1 2023 S2 2024 Q1
Net sales 1 - 2,118 1,118
EBITDA - - -
EBIT - 524.2 -
Operating Margin - 24.75% -
Earnings before Tax (EBT) - 569 -
Net income 491.5 478 -
Net margin - 22.57% -
EPS 0.6500 - -
Dividend per Share - - -
Announcement Date 30/08/23 28/03/24 -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 3,541 3,551 4,191 5,046 - 5,735 6,217 7,100
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - - - 532 900 1,367
ROE (net income / shareholders' equity) 9.32% 8.63% 9.52% 11.8% - 15.3% 16.1% 16.8%
ROA (Net income/ Total Assets) 7.76% 6.96% 7.72% - - 11.5% 12.3% 12.7%
Assets 1 6,481 4,237 7,209 - - 9,819 10,680 11,893
Book Value Per Share 2 7.400 7.660 7.810 8.450 - 9.290 10.20 11.20
Cash Flow per Share 0.4700 - 0.9300 - - - - -
Capex 1 88.4 66 93.6 - - 164 173 208
Capex / Sales 3.27% 2.49% 2.9% - - 3.13% 2.86% 2.97%
Announcement Date 31/03/20 30/03/21 29/03/22 30/03/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for China Shineway Pharmaceutical Group Limited

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.156 CNY
Average target price
13.01 CNY
Spread / Average Target
+42.11%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED Stock China Shineway Pharmaceutical Group Limited
+36.04% 943M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+22.69% 43.81B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+24.96% 23.01B
SANDOZ GROUP AG Stock Sandoz Group AG
+18.00% 15.27B
CIPLA LIMITED Stock Cipla Limited
+8.91% 13.68B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+42.72% 11.96B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-7.47% 6.98B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+12.22% 5.59B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 2877 Stock
  4. Financials China Shineway Pharmaceutical Group Limited